PF-9363

Cat. No.:	HY-132283
CAS No.:	2569009-58-9
Molecular Formula:	$C_{20}H_{20}N_4O_6S$
Molecular Weight:	444.46
Target:	Histone Acetyltransferase
Pathway:	Epigenetics
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (112.50 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.2499 mL	11.2496 mL	22.4992 mL
	5 mM	0.4500 mL	2.2499 mL	4.4998 mL
	10 mM	0.2250 mL	1.1250 mL	2.2499 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.08 mg/mL (4.68 mM); Suspended solution; Need ultrasonic
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

PF-9363 (CTx-648) is a first-in-class potent and high selective KAT6A/KAT6B inhibitor. PF-9363 can be used for the research of cancer[1][2].

IC_{50} & Target

MOZ/MORF

In Vitro

PF-9363 (0~1 μM; 1 day; ZR75-1, T47D and MCF7 cells) down-regulates the expression of H3K23Ac biomarker[1].
?PF-9363 leads to down regulation of a specific set of genes involved in ESR1 pathway, cell cycle and stem cell pathways. PF-

	9363 shows that the IC_{50} values for ZR75-1 and T47D are 0.3 nM and 0.9 nM[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis[1]

Cell Line:	ZR75-1, T47D and MCF7 cells
Concentration:	0~1 μM
Incubation Time:	1 day
Result:	Down-regulated the expression of H3K23Ac biomarker.

In Vivo	PF-9363 shows strong anti-tumor activity in patient-derived xenograft models[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Cell Biol. 2023 Sep;25(9):1346-1358.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Shikhar S, et al. First-in-class KAT6A/KAT6B Inhibitor CTx-648 (PF-9363) Demonstrates Potent Anti-tumor Activity in ER+ Breast Cancer with KAT6A Dysregulation

[2]. WO2020254946

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA